Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
275 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Stroke - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Stroke - Pipeline Review, H2 2014', provides an overview of the Stroke's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Stroke and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Stroke - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Stroke and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Stroke pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Stroke - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Stroke pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 Introduction 6 Stroke Overview 7 Therapeutics Development 8 Stroke - Therapeutics under Development by Companies 10 Stroke - Therapeutics under Investigation by Universities/Institutes 16 Stroke - Pipeline Products Glance 18 Stroke - Products under Development by Companies 22 Stroke - Products under Investigation by Universities/Institutes 27 Stroke - Companies Involved in Therapeutics Development 29 Stroke - Therapeutics Assessment 83 Drug Profiles 94 Stroke - Recent Pipeline Updates 216 Stroke - Dormant Projects 253 Stroke - Discontinued Products 256 Stroke - Product Development Milestones 257 Appendix 263
List of Tables Number of Products under Development for Stroke, H2 2014 19 Number of Products under Development for Stroke - Comparative Analysis, H2 2014 20 Number of Products under Development by Companies, H2 2014 22 Number of Products under Development by Companies, H2 2014 (Contd..1) 23 Number of Products under Development by Companies, H2 2014 (Contd..2) 24 Number of Products under Development by Companies, H2 2014 (Contd..3) 25 Number of Products under Development by Companies, H2 2014 (Contd..4) 26 Number of Products under Investigation by Universities/Institutes, H2 2014 28 Comparative Analysis by Late Stage Development, H2 2014 29 Comparative Analysis by Clinical Stage Development, H2 2014 30 Comparative Analysis by Early Stage Development, H2 2014 31 Comparative Analysis by Unknown Stage Development, H2 2014 32 Products under Development by Companies, H2 2014 33 Products under Development by Companies, H2 2014 (Contd..1) 34 Products under Development by Companies, H2 2014 (Contd..2) 35 Products under Development by Companies, H2 2014 (Contd..3) 36 Products under Development by Companies, H2 2014 (Contd..4) 37 Products under Investigation by Universities/Institutes, H2 2014 38 Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 39 Stroke - Pipeline by Acorda Therapeutics, Inc., H2 2014 40 Stroke - Pipeline by advanceCor GmbH, H2 2014 41 Stroke - Pipeline by Affibody AB, H2 2014 42 Stroke - Pipeline by AGY Therapeutics, Inc., H2 2014 43 Stroke - Pipeline by Anavex Life Sciences Corp., H2 2014 44 Stroke - Pipeline by APT Therapeutics, Inc., H2 2014 45 Stroke - Pipeline by ArmaGen Technologies, Inc., H2 2014 46 Stroke - Pipeline by Cardax Pharmaceuticals, Inc., H2 2014 47 Stroke - Pipeline by Cellular Biomedicine Group, Inc., H2 2014 48 Stroke - Pipeline by CHA Bio & Diostech Co., Ltd., H2 2014 49 Stroke - Pipeline by CoDa Therapeutics, Inc., H2 2014 50 Stroke - Pipeline by D-Pharm Ltd., H2 2014 51 Stroke - Pipeline by Diakron Pharmaceuticals, Inc., H2 2014 52 Stroke - Pipeline by Dong Wha Pharma Co., Ltd., H2 2014 53 Stroke - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 54 Stroke - Pipeline by Fina Biotech, H2 2014 55 Stroke - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2014 56 Stroke - Pipeline by GliaMed, Inc., H2 2014 57 Stroke - Pipeline by Green Cross Corporation, H2 2014 58 Stroke - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 59 Stroke - Pipeline by International Stem Cell Corporation, H2 2014 60 Stroke - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2014 61 Stroke - Pipeline by Kolon Life Science, Inc., H2 2014 62 Stroke - Pipeline by Lacer, S.A., H2 2014 63 Stroke - Pipeline by LegoChem Biosciences, Inc, H2 2014 64 Stroke - Pipeline by Ligand Pharmaceuticals, Inc., H2 2014 65 Stroke - Pipeline by Living Cell Technologies Limited, H2 2014 66 Stroke - Pipeline by Mapreg S.A.S., H2 2014 67 Stroke - Pipeline by Mast Therapeutics, Inc., H2 2014 68 Stroke - Pipeline by Medestea Research & Production S.p.A., H2 2014 69 Stroke - Pipeline by Mesoblast Limited, H2 2014 70 Stroke - Pipeline by Mnemosyne Pharmaceuticals, Inc., H2 2014 71 Stroke - Pipeline by Neuralstem, Inc., H2 2014 72 Stroke - Pipeline by Neuren Pharmaceuticals Limited, H2 2014 73 Stroke - Pipeline by New Haven Pharmaceuticals, Inc., H2 2014 74 Stroke - Pipeline by Novavax, Inc., H2 2014 75 Stroke - Pipeline by Omeros Corporation, H2 2014 76 Stroke - Pipeline by Pharmicell Co., Ltd., H2 2014 77 Stroke - Pipeline by Phoenix Biotechnology, Inc., H2 2014 78 Stroke - Pipeline by Phylogica Limited, H2 2014 79 Stroke - Pipeline by PhytoHealth Corporation, H2 2014 80 Stroke - Pipeline by Pozen, Inc., H2 2014 81 Stroke - Pipeline by Q Therapeutics, Inc., H2 2014 82 Stroke - Pipeline by ReCyte Therapeutics, Inc., H2 2014 83 Stroke - Pipeline by Regado Biosciences, Inc., H2 2014 84 Stroke - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2014 85 Stroke - Pipeline by Saneron CCEL Therapeutics, Inc., H2 2014 86 Stroke - Pipeline by StemCells, Inc., H2 2014 87 Stroke - Pipeline by SynZyme Technologies, LLC, H2 2014 88 Stroke - Pipeline by Targazyme, Inc., H2 2014 89 Stroke - Pipeline by Vicore Pharma AB, H2 2014 90 Stroke - Pipeline by Virogenomics, Inc., H2 2014 91 Stroke - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2014 92 Stroke - Pipeline by Xigen SA, H2 2014 93 Assessment by Monotherapy Products, H2 2014 94 Number of Products by Stage and Target, H2 2014 96 Number of Products by Stage and Mechanism of Action, H2 2014 99 Number of Products by Stage and Route of Administration, H2 2014 102 Number of Products by Stage and Molecule Type, H2 2014 104 Stroke Therapeutics - Recent Pipeline Updates, H2 2014 227 Stroke - Dormant Projects, H2 2014 264 Stroke - Discontinued Products, H2 2014 267
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
